S M Mishra1, J Dykeman2, T T Sajobi3, A Trivedi1, M Almekhlafi4, S I Sohn5, S Bal6, E Qazi7, A Calleja8, M Eesa9, M Goyal10, A M Demchuk10, B K Menon11. 1. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.). 2. Radiology (J.D., M.A., M.E., M.G., A.M.D., B.K.M.). 3. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.) Community Health Sciences (T.T.S., B.K.M.), University of Calgary, Calgary, Alberta, Canada Hotchkiss Brain Institute (T.T.S., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada. 4. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.) Radiology (J.D., M.A., M.E., M.G., A.M.D., B.K.M.) Faculty of Medicine (M.A.), King Abdulaziz University, Jeddah, Saudi Arabia Seaman Family MR Center (M.A., E.Q., M.E., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada. 5. Department of Neurology (S.I.S.), Dongsan Medical Center, Keimyung University, Daegu, South Korea. 6. Department of Neurology (S.B.), University of Manitoba, Winnipeg, Manitoba, Canada. 7. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.) Seaman Family MR Center (M.A., E.Q., M.E., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada. 8. Department of Neurology (A.C.), Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain. 9. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.) Radiology (J.D., M.A., M.E., M.G., A.M.D., B.K.M.) Seaman Family MR Center (M.A., E.Q., M.E., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada. 10. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.) Radiology (J.D., M.A., M.E., M.G., A.M.D., B.K.M.) Seaman Family MR Center (M.A., E.Q., M.E., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada Hotchkiss Brain Institute (T.T.S., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada. 11. From the Departments of Clinical Neurosciences (S.M.M., T.T.S., A.T., M.A., E.Q., M.E., M.G., A.M.D., B.K.M.) Radiology (J.D., M.A., M.E., M.G., A.M.D., B.K.M.) Community Health Sciences (T.T.S., B.K.M.), University of Calgary, Calgary, Alberta, Canada Seaman Family MR Center (M.A., E.Q., M.E., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada Hotchkiss Brain Institute (T.T.S., M.G., A.M.D., B.K.M.), Calgary, Alberta, Canada. docbijoymenon@gmail.com.
Abstract
BACKGROUND AND PURPOSE: An ability to predict early reperfusion with IV tPA in patients with acute ischemic stroke and intracranial clots can help clinicians decide if additional intra-arterial therapy is needed or not. We explored the association between novel clot characteristics on baseline CTA and early reperfusion with IV tPA in patients with acute ischemic stroke by using classification and regression tree analysis. MATERIALS AND METHODS: Data are from patients with acute ischemic stroke and proximal anterior circulation occlusions from the Calgary CTA data base (2003-2012) and the Keimyung Stroke Registry (2005-2009). Patients receiving IV tPA followed by intra-arterial therapy were included. Clot location, length, residual flow within the clot, ratio of contrast Hounsfield units pre- and postclot, and the M1 segment origin to the proximal clot interface distance were assessed on baseline CTA. Early reperfusion (TICI 2a and above) with IV tPA was assessed on the first angiogram. RESULTS: Two hundred twenty-eight patients (50.4% men; median age, 69 years; median baseline NIHSS score, 17) fulfilled the inclusion criteria. Median symptom onset to IV tPA time was 120 minutes (interquartile range = 70 minutes); median IV tPA to first angiography time was 70.5 minutes (interquartile range = 62 minutes). Patients with residual flow within the clot were 5 times more likely to reperfuse than those without it. Patients with residual flow and a shorter clot length (≤15 mm) were most likely to reperfuse (70.6%). Patients with clots in the M1 MCA without residual flow reperfused more if clots were distal and had a clot interface ratio in Hounsfield units of <2 (36.8%). Patients with proximal M1 clots without residual flow reperfused 8% of the time. Carotid-T/-L occlusions rarely reperfused (1.7%). Interrater reliability for these clot characteristics was good. CONCLUSIONS: Our study shows that clot characteristics on CTA help physicians estimate a range of early reperfusion rates with IV tPA.
BACKGROUND AND PURPOSE: An ability to predict early reperfusion with IV tPA in patients with acute ischemic stroke and intracranial clots can help clinicians decide if additional intra-arterial therapy is needed or not. We explored the association between novel clot characteristics on baseline CTA and early reperfusion with IV tPA in patients with acute ischemic stroke by using classification and regression tree analysis. MATERIALS AND METHODS: Data are from patients with acute ischemic stroke and proximal anterior circulation occlusions from the Calgary CTA data base (2003-2012) and the Keimyung Stroke Registry (2005-2009). Patients receiving IV tPA followed by intra-arterial therapy were included. Clot location, length, residual flow within the clot, ratio of contrast Hounsfield units pre- and postclot, and the M1 segment origin to the proximal clot interface distance were assessed on baseline CTA. Early reperfusion (TICI 2a and above) with IV tPA was assessed on the first angiogram. RESULTS: Two hundred twenty-eight patients (50.4% men; median age, 69 years; median baseline NIHSS score, 17) fulfilled the inclusion criteria. Median symptom onset to IV tPA time was 120 minutes (interquartile range = 70 minutes); median IV tPA to first angiography time was 70.5 minutes (interquartile range = 62 minutes). Patients with residual flow within the clot were 5 times more likely to reperfuse than those without it. Patients with residual flow and a shorter clot length (≤15 mm) were most likely to reperfuse (70.6%). Patients with clots in the M1 MCA without residual flow reperfused more if clots were distal and had a clot interface ratio in Hounsfield units of <2 (36.8%). Patients with proximal M1 clots without residual flow reperfused 8% of the time. Carotid-T/-L occlusions rarely reperfused (1.7%). Interrater reliability for these clot characteristics was good. CONCLUSIONS: Our study shows that clot characteristics on CTA help physicians estimate a range of early reperfusion rates with IV tPA.
Authors: Diederik M Somford; Paul J Nederkoorn; Dirk R Rutgers; L Jaap Kappelle; Willem P T M Mali; Jeroen van der Grond Journal: Radiology Date: 2002-06 Impact factor: 11.105
Authors: Christian H Riedel; Philip Zimmermann; Ulf Jensen-Kondering; Robert Stingele; Günther Deuschl; Olav Jansen Journal: Stroke Date: 2011-04-07 Impact factor: 7.914
Authors: Volker Puetz; Imanuel Dzialowski; Michael D Hill; Suresh Subramaniam; P N Sylaja; Andrea Krol; Christine O'Reilly; Mark E Hudon; William Y Hu; Shelagh B Coutts; Philip A Barber; Timothy Watson; Jayanta Roy; Andrew M Demchuk Journal: Int J Stroke Date: 2008-11 Impact factor: 5.266
Authors: Bijoy K Menon; Eric E Smith; Shelagh B Coutts; Donald G Welsh; James E Faber; Mayank Goyal; Michael D Hill; Andrew M Demchuk; Zaheed Damani; Kyung-Hee Cho; Hyuk-Won Chang; Jeong-Ho Hong; Sung Il Sohn Journal: Ann Neurol Date: 2013-09-04 Impact factor: 10.422
Authors: Parham Moftakhar; Joey D English; Daniel L Cooke; Warren T Kim; Charles Stout; Wade S Smith; Christopher F Dowd; Randall T Higashida; Van V Halbach; Steven W Hetts Journal: Stroke Date: 2012-10-30 Impact factor: 7.914
Authors: Max Wintermark; Gregory W Albers; Joseph P Broderick; Andrew M Demchuk; Jochen B Fiebach; Jens Fiehler; James C Grotta; Gary Houser; Tudor G Jovin; Kennedy R Lees; Michael H Lev; David S Liebeskind; Marie Luby; Keith W Muir; Mark W Parsons; Rüdiger von Kummer; Joanna M Wardlaw; Ona Wu; Albert J Yoo; Andrei V Alexandrov; Jeffry R Alger; Richard I Aviv; Roland Bammer; Jean-Claude Baron; Fernando Calamante; Bruce C V Campbell; Trevor C Carpenter; Søren Christensen; William A Copen; Colin P Derdeyn; E Clarke Haley; Pooja Khatri; Kohsuke Kudo; Maarten G Lansberg; Lawrence L Latour; Ting-Yim Lee; Richard Leigh; Weili Lin; Patrick Lyden; Grant Mair; Bijoy K Menon; Patrik Michel; Robert Mikulik; Raul G Nogueira; Leif Ostergaard; Salvador Pedraza; Christian H Riedel; Howard A Rowley; Pina C Sanelli; Makoto Sasaki; Jeffrey L Saver; Pamela W Schaefer; Peter D Schellinger; Georgios Tsivgoulis; Lawrence R Wechsler; Philip M White; Greg Zaharchuk; Osama O Zaidat; Stephen M Davis; Geoffrey A Donnan; Anthony J Furlan; Werner Hacke; Dong-Wha Kang; Chelsea Kidwell; Vincent N Thijs; Götz Thomalla; Steven J Warach Journal: Stroke Date: 2013-07-16 Impact factor: 7.914
Authors: W Qiu; H Kuang; J Nair; Z Assis; M Najm; C McDougall; B McDougall; K Chung; A T Wilson; M Goyal; M D Hill; A M Demchuk; B K Menon Journal: AJNR Am J Neuroradiol Date: 2018-12-20 Impact factor: 3.825
Authors: Charlie Chia-Tsong Hsu; Gigi Nga Chi Kwan; Sachintha Hapugoda; Michelle Craigie; Trevor William Watkins; E Mark Haacke Journal: Neuroradiol J Date: 2017-01-01
Authors: Mina Park; Kyung-Eun Kim; Na-Young Shin; Seung-Koo Lee; Soo Mee Lim; Dongbeom Song; Ji Hoe Heo; Jin Woo Kim; Se Won Oh Journal: Eur Radiol Date: 2015-09-22 Impact factor: 5.315
Authors: Bijoy K Menon; Emmad Qazi; Vivek Nambiar; Lydia D Foster; Sharon D Yeatts; David Liebeskind; Tudor G Jovin; Mayank Goyal; Michael D Hill; Thomas A Tomsick; Joseph P Broderick; Andrew M Demchuk Journal: Stroke Date: 2015-03-19 Impact factor: 7.914
Authors: M A Almekhlafi; W G Kunz; B K Menon; R A McTaggart; M V Jayaraman; B W Baxter; D Heck; D Frei; C P Derdeyn; T Takagi; A H Aamodt; I M R Fragata; M D Hill; A M Demchuk; M Goyal Journal: AJNR Am J Neuroradiol Date: 2019-01-31 Impact factor: 3.825
Authors: C C McDougall; L Chan; S Sachan; J Guo; R G Sah; B K Menon; A M Demchuk; M D Hill; N D Forkert; C D d'Esterre; P A Barber Journal: AJNR Am J Neuroradiol Date: 2020-10-01 Impact factor: 3.825